Impath
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Impath Inc., a New York based corporation, was a provider of cancer related laboratory services. Impath filed for bankruptcy protection in September 2003.[1]
Beginning in the late 1990s and until 2003, its business withered away, but its executives continued to talk up their stock and the profitability of their impending anti-cancer breakthroughs.
In May 2004, Genzyme acquired several of Impath's laboratories and cancer-testing technologies.[2][3]
In September 2005 the United States Securities and Exchange Commission took action against former CEO Anuradha Saad and her colleagues, alleging fraudulent accounting.[1] The same month Saad pleaded guilty to two counts of soliciting proxies containing false statements.[1] It was also alleged that Saad improperly charged $120,000 in personal expenses to Impath.[1] On Tuesday, May 30, 2006, the former president and chief operating officer of Impath, Richard P. Adelson, received a sentence from district court judge Jed S. Rakoff.[1]
References
- ^ a b c d e Greg Levine (January 18, 2006). "Impath Ex-CEO Jailed On Art, Furniture Expenses". Forbes. Retrieved 2011-04-13.
{{cite web}}: Italic or bold markup not allowed in:|publisher=(help) - ^ Milford Daily News. 05-04-2004 http://www.milforddailynews.com/business/x1528515155. Retrieved 2011-12-15.
{{cite journal}}: Check date values in:|date=(help); Missing or empty|title=(help) - ^ "Genzyme Timeline" (PDF). Retrieved 2011-12-15.
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |